A clinical-stage biotechnology company developing gene-based therapies for cancer and diabetes. Its lead programs focus on delivering tumor-suppressor genes for lung cancer and exploring gene therapy approaches for Type 1 and Type 2 diabetes. Investors track the company for clinical trial progress, ...
1 member of Congress has disclosed 4 trades in Genprex, Inc. (GNPX), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| 2025-11-07 | Tim Moore | buy | $1K – $15K |
| 2025-10-29 | Tim Moore | buy | $15K – $50K |